DarioHealth opened higher at $2.59, compared with its previous close of $2.13. In the last trading session, the stock traded between $1.57 and $2.60. It showed a downward intraday trend.
An investment of $100 made 5 years ago in DarioHealth is now worth
$ 0.48
Resulting in a loss of
$ 99.52 (99.52%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.46 (-21.41%)
Day High
$2.60
Day Low
$1.57
Day Open
$2.59
Prev Close
$2.13
Volume
1,48,910
1W Return
-44.31%
1M Return
-69.24%
3M Return
-78.26%
6M Return
-79.07%
1Y Return
-86.26%
Market Cap ($ Mn)
16
PE Ratio
-
PB Ratio
0.90
PEG Ratio
-
ROE
-59.16%
ROCE
-39.03%
EPS (TTM)
$-1.08
1 Week
-44.31%
1 Month
-69.24%
3 Months
-78.26%
6 Months
-79.07%
9 Months
-84.82%
DarioHealth Q3FY26 Results: Revenue up 6%, operating loss narrows 15%
Revenue rose 6% YoY to $5.3 million; operating loss narrowed 15% to $8.0 million. Direct-to-consumer revenue grew 48% YoY, now comprising 53% of total revenue. New Jersey health plan win adds 1.5 million covered lives via Amwell channel. Management reaffirms trajectory to reach breakeven by 2028.
TodayDarioHealth secures New Jersey health plan contract through Amwell
DarioHealth secured a contract with a leading New Jersey health plan. The deal covers approximately 1.5 million covered lives. Agreement was facilitated through strategic partner Amwell. Revenue generation is expected to begin in Q1 2027. This is the third large state health plan signed via Amwell in 12 months.
1mo agoAlliance Global Partners initiates DarioHealth coverage with Buy rating
Alliance Global Partners analyst Scott Henry initiates coverage on DarioHealth (NASDAQ: DRIO) with a Buy rating and a $12 price target. This marks the firm's first formal recommendation on the healthcare tech stock.
2mo agoDarioHealth Q2 Results: Adj. EPS beats estimates, sales miss
DarioHealth delivered a mixed second-quarter performance, with adjusted EPS of $(0.72) beating the $(1.22) estimate by 40.98 percent and improving 82.44 percent year-over-year. However, sales of $5.177 million missed the $5.923 million forecast by 12.59 percent, down 3.58 percent from the prior year's $5.369 million. The results highlight a divergence where profitability improved despite a contraction in top-line revenue.
3mo agoDarioHealth Q2 Results: Earnings call set for Aug 11
DarioHealth Corp. will release its Q2 2026 financial results on August 11, 2026. The AI-driven healthcare technology firm will hold an earnings call at 8:30 a.m. ET with CEO Erez Raphael and CFO Chen Franco-Yehuda. A replay will be available until August 25, 2026.
3mo agoDarioHealth launches GLP-1 program with Fall 2026 commercial availability
DarioHealth introduces a GLP-1 program via Beluga Health, integrating clinical oversight into its platform. Targeting reduced employer coverage, it launches via three channels with Fall 2026 availability. Revenue is expected from late 2026, ramping through 2027.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 5 years ago in DarioHealth is now worth
$ 0.48
Resulting in a loss of
$ 99.52 (99.52%)
Note: Past profits do not guarantee future returns.
